Acadian Asset Management
NTLA icon

Acadian Asset Management’s Intellia Therapeutics NTLA Stock Holding History

Acadian Asset Management’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-2,607
Closed -$32K – 2161
2026
Q1 		$32K Buy
+2,607
New +$33.2K ﹤0.01% 1902
2021
Q1 		– Sell
-583
Closed -$32K – 2237
2020
Q4 		$32K Buy
+583
New +$21.2K ﹤0.01% 2052
2017
Q3 		– Sell
-74,230
Closed -$1.19M – 1490
2017
Q2 		$1.19M Sell
74,230
-21,923
-23% -$306K 0.01% 673
2017
Q1 		$1.35M Buy
+96,153
New +$1.29M 0.01% 710

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Acadian Asset Management's NTLA Position: Q2 2026 in Review

Acadian Asset Management sold out of Intellia Therapeutics (NTLA) in Q2 2026, closing a stake of 2,607 shares — an estimated $32K sold.

Acadian Asset Management first reported a position in NTLA in Q1 2017 and held it in 4 quarters. The position peaked at $1.35M in Q1 2017. 328 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • Acadian Asset Management reported no remaining Intellia Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Acadian Asset Management sold 2,607 Intellia Therapeutics shares in Q2 2026, an estimated $32K.
  • Acadian Asset Management first reported a position in Intellia Therapeutics in Q1 2017 and held it in 4 quarters.
  • Acadian Asset Management's Intellia Therapeutics position peaked at $1.35M in Q1 2017.
  • 328 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on Acadian Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.